Sichenzia Ross Friedman Ference LLP Represents BioPharmX Corporation in $930,000 Registered Direct Offering
Press Release – New York, NY – September 29, 2016 – Sichenzia Ross Friedman Ference LLP announced today that it has represented BioPharmX Corporation (NYSE. MKT “ BPMX) in a Registered Direct public offering of 1,550,000 registered shares of its common stock at a price of $.60 per share and 1,240,000 unregistered warrants to purchase common stock at an exercise price of $.75 per share for gross proceeds to BPMX of $930,000. Rodman & Renshaw a Unit of H.C. Wainwright & Co., LLC acted as the exclusive Placement Agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, Marcelle Balcombe and Counsel Jeff Cahlon.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
- Sichenzia Ross Ference LLP Congratulates INmune Bio Inc., on Initial Public Offering - April 10, 2019
- FDA sets first hearing on CBD in May as the agency looks at legalizing the cannabis compound in food and drinks - April 4, 2019